Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants

Min Wang

Jinyue Yang

Yahong Tan

Shuofeng Yuan

Guoli Shi

Qi Peng

The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, School of Basic Medical Sciences, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Yongqi Li

Vincent Kwok-Man Poon

Chris Chung-Sing Chan

Na Xiao

Anna Jinxia Zhang

Yubin Xie

Junhua Li

State Key Joint Laboratory of Environment Simulation and Pollution Control, School of Environment

Hao Luo

Yaning Fu

Yong Chen

Alex A. Compton

Youming Zhang

Helmholtz International Lab for Anti-Infectives, State Key Laboratory of Microbial Technology

Yang Yang

George Fu Gao

National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention

Hongwei Hou

College of Chemistry

Jasper Fuk-Woo Chan

Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong

Yizhen Yin

State Key Laboratory of Microbial Technology, Institute of Microbial Technology

Yi Shi

School of Materials Science and Engineering, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Guangdong Functional Biomaterials Engineering Technology Research Center